for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

resTORbio, Inc.

TORC.OQ

Latest Trade

1.17USD

Change

-0.01(-0.85%)

Volume

77,431

Today's Range

1.15

 - 

1.17

52 Week Range

0.94

 - 

13.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.18
Open
1.17
Volume
77,431
3M AVG Volume
20.86
Today's High
1.17
Today's Low
1.15
52 Week High
13.50
52 Week Low
0.94
Shares Out (MIL)
36.44
Market Cap (MIL)
43.00
Forward P/E
-0.52
Dividend (Yield %)
--

Latest Developments

More

ResTORbio Announces Phase 3 PROTECTOR 1 Trial Of RTB101 In Clinically Symptomatic Respiratory Illness Did Not Meet Primary Endpoint

Restorbio Reports Third Quarter 2019 Financial Results And Corporate Update

Restorbio Posts Q2 Loss Per Share Of $0.51

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About resTORbio, Inc.

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1). Its initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR inhibitors, such as everolimus. Its product pipeline includes the TORC1 program that includes the development of RTB101 for various indications. The indications include respiratory tract infections, heart failure with preserved ejection fraction, autophagy related neurodegenerative diseases and other indications. The Company is developing RTB101 in a Phase II b clinical trial.

Industry

Biotechnology & Drugs

Contact Info

500 Boylston St Fl 12

+1.617.4822333

https://www.restorbio.com/

Executive Leadership

Chen Schor

President, Chief Executive Officer, Director

John J. McCabe

Vice President - Finance

Erkan Baloglu

Vice President - Drug Discovery and Medicinal Chemistry

Lloyd Klickstein

Chief Scientific Officer

Joan Mannick

Chief Medical Officer

Key Stats

3.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-8.420

2018

-1.420

2019(E)

-2.268
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-54.40
Return on Equity (TTM)
-49.80

Latest News

Latest News

ResTORbio stops testing lead drug for respiratory illness; shares crash

Shares of drug developer ResTORbio Inc plunged more than 80% to a record low on Friday after a late-stage trial failure prompted the company to abandon testing its lead drug as a treatment for respiratory illness.

ResTORbio's respiratory illness drug fails late-stage study

ResTORbio Inc's said on Friday its lead drug missed the main goal in a late-stage testing in patients aged above 65 with respiratory illness.

BRIEF-resTORbio Announces Pricing Of Initial Public Offering

* RESTORBIO-ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 5.7 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $15.00 PER SHARE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up